Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Capital Leases (2016 - 2021)

Adma Biologics' Capital Leases history spans 10 years, with the latest figure at $6.4 million for Q1 2021.

  • For Q1 2021, Capital Leases rose 250.48% year-over-year to $6.4 million; the TTM value through Mar 2021 reached $6.4 million, up 250.48%, while the annual FY2020 figure was $4.3 million, 232.79% up from the prior year.
  • Capital Leases reached $6.4 million in Q1 2021 per ADMA's latest filing, up from $4.3 million in the prior quarter.
  • In the past five years, Capital Leases ranged from a high of $6.4 million in Q1 2021 to a low of $15319.0 in Q1 2017.
  • Average Capital Leases over 5 years is $1.8 million, with a median of $1.4 million recorded in 2019.
  • Peak YoY movement for Capital Leases: skyrocketed 993.69% in 2019, then increased 25.33% in 2020.
  • A 5-year view of Capital Leases shows it stood at $15319.0 in 2017, then surged by 677.34% to $119080.0 in 2018, then surged by 993.69% to $1.3 million in 2019, then surged by 232.79% to $4.3 million in 2020, then surged by 48.12% to $6.4 million in 2021.
  • Per Business Quant, the three most recent readings for ADMA's Capital Leases are $6.4 million (Q1 2021), $4.3 million (Q4 2020), and $2.9 million (Q3 2020).